In a significant milestone for Alzheimer’s disease treatment, the U.S. Food and Drug Administration (FDA) recently approved a new drug, Kisunla™ (donanemab-azbt). This approval marks a
New York Mets legend Bud Harrelson, who bravely shared his Alzheimer’s diagnosis in 2018, passed away earlier this year. Harrelson, renowned for his career as a
UC Berkeley scientists have made a significant breakthrough in understanding how stress responses in brain cells can be turned off, a discovery that could pave the
The Alzheimer’s drug development pipeline for 2024 is bustling with activity, featuring 171 ongoing studies and 134 drugs in clinical trials. Notable treatments in the pipeline
Researchers at Ruhr-University Bochum have developed a groundbreaking group training tool aimed at preventing dementia. This innovative tool focuses on cognitive training and lifestyle changes to
Biogen has announced the discontinuation of Aduhelm, its first Alzheimer’s treatment, to reallocate resources towards Leqembi, a newer drug that has shown promise in slowing the
In a groundbreaking study, scientists have uncovered a potential link between drugs used to treat erectile dysfunction and a reduced risk of Alzheimer’s disease. This research,
